Recruiting
Phase 2
Phase 3

A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)

Sponsor:

ALX Oncology Inc.

Code:

NCT05002127

Conditions

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Evorpacept (ALX148)

Trastuzumab

Ramucirumab

Paclitaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information